Eli Lilly is striking a $1.9 billion gene-editing deal to develop inherited kidney disease treatments
The agreement gives Lilly exclusive rights to Ascidian's RNA exon-editing technology, which repairs faulty genes without altering a patient's DNA
Overview
The agreement gives Lilly exclusive rights to Ascidian's RNA exon-editing technology, which repairs faulty genes without altering a patient's DNA
Source
Originally published at qz.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.
